Display Settings:

Format

Send to:

Choose Destination
Am J Manag Care. 2006 Oct;12(11 Suppl):S325-31.

Cost efficiency and formulary considerations for statin therapy.

Author information

  • 1The Regence Group, 1211 W Myrtle, #110, Boise, ID 83701, USA. tkillilea.id@regence.com

Abstract

Extensive epidemiologic evidence and reports issued by the National Cholesterol Education Program have repeatedly identified low-density lipoprotein cholesterol (LDL-C) as the primary target in reducing the primary and secondary risk of coronary events. With recent evidence supporting a more aggressive approach using higher potency statins, and a lower threshold for initiating drug therapy for high-risk patients, providers and administrators in managed care are charged with finding the most effective and cost-effective means of attaining these goals. Changes in the market, such as newer high-potency statins and statin combinations available at lower cost and expiration of patents on widely accepted brand drugs, have provided practitioners with the ability to reduce LDL-C at lower costs than ever. The cost-efficiency analysis presented here finds that, for low-to-moderate reduction (<40%), generic lovastatin and simvastatin provide the lowest cost per 1% LDL-C reduction. Similarly, for reduction greater than 40%, branded rosuvastatin and ezetimibe/simvastatin have the lowest cost per 1% reduction.

PMID:
17042675
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Managed Care & Healthcare Communications, LLC
    Loading ...
    Write to the Help Desk